Valnoctamide
| Names | |
|---|---|
| Preferred IUPAC name 2-Ethyl-3-methylpentanamide | |
| Identifiers | |
| 3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.021.849 | 
| EC Number | 
 | 
| KEGG | |
| MeSH | valnoctamide | 
| PubChem CID | |
| RTECS number | 
 | 
| UNII | |
| CompTox Dashboard (EPA) | |
| 
 | |
| 
 | |
| Properties | |
| C8H17NO | |
| Molar mass | 143.230 g·mol−1 | 
| Appearance | White crystals | 
| log P | 1.885 | 
| Pharmacology | |
| N05CM13 (WHO) | |
| 
 | |
| Pharmacokinetics: | |
| 94% | |
| Hepatic | |
| 10 hours | |
| Hazards | |
| GHS labelling: | |
| Warning | |
| H302 | |
| Lethal dose or concentration (LD, LC): | |
| LD50 (median dose) | 760 mg kg−1 (oral, rat) | 
| Related compounds | |
| Related alkanamides | Valpromide | 
| Related compounds | |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references | |
Valnoctamide (INN, USAN) has been used in France as a sedative-hypnotic since 1964. It is a structural isomer of valpromide, a valproic acid prodrug; unlike valpromide, however, valnoctamide is not transformed into its homologous acid, valnoctic acid, in vivo.